Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Melanoma 2Uveal Melanoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

neratinib 1fludarabine 1famitinib 1encorafenib 1camrelizumab 1Valproic Acid 1Taxes 1TPI-287 1Sodium Selenite 1Nivolumab 1Ifosfamide 1Gemcitabine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Disease Progression × Valproic Acid × Clear all
NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Virginia Commonwealth University

Phase 1/2 Recruiting
83 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡